Overview
Innovative Medicines based on
ImmunoModulatory Biologics
-
Pipeline
-
Overview
We have adopted an accelerated R&D model for the innovative immunomodulatory antibody drug development utilizing our proprietary platform technology as well as in-licensing novel antibody assets.
| Item | Portfolio | Code | Indication | Target | Discovery | Early Development |
Clinical Development |
Remark | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Development Strategy |
Target PoC | Screening | Candidate | Proof of Indication & Process Development |
Non-clinical | |||||||
| Pipeline | Autoimmune | IMB-101
(OXTIMA) |
Autoimmune
disease |
OX40L/TNF | Worldwide
Exclusive License |
|||||||
| IMB-102 | Autoimmune
disease |
OX40L | Worldwide
Exclusive License |
|||||||||
|
Immune
Oncology |
IMB-201 | Cancer | HLA-G | |||||||||
| IMB-202 | Cancer | Nondisclosure | ||||||||||
| IMB-401 | Cancer | Nondisclosure | In-house patent | |||||||||
| Others | IMB-301 | - | Nondisclosure | - | ||||||||
좌우로 스크롤 하시면 전체 내용을 확인할 수 있습니다.
- President(CEO) : Gyongsik Ha
- 260, Changnyong-daero, Yeongtong-gu, Suwon-si, Gyeonggi-do, Republic of Korea